I. Andrulis

发表

Identification and characterization of missense alterations in the BRCA1 associated RING domain (BARD1) gene in breast and ovarian cancer

M. Sauer, I. Andrulis, 2005, Journal of Medical Genetics.

Identification and characterization of missense alterations in the BRCA 1 associated RING domain ( BARD 1 ) gene in breast and ovarian cancer

M. Sauer, I. Andrulis, 2005 .

Genetic insights into biological mechanisms governing human ovarian ageing

Boe, S. Bandinelli, M. Beckmann, 2021, Nature.

Analysis of mRNA from microdissected frozen tissue sections without RNA isolation.

I. Andrulis, M. Redston, M. To, 1998, The American journal of pathology.

The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers

J. Benítez, R. Eeles, A. Spurdle, 2009, British Journal of Cancer.

Multigene testing of moderate-risk genes: be mindful of the missense

E. John, M. Southey, S. Tavtigian, 2016, Journal of Medical Genetics.

Functional characterization of novel presenilin-2 variants identified in human breast cancers

I. Andrulis, J. Knight, A. Bernstein, 2006, Oncogene.

Rare mutations in XRCC2 increase the risk of breast cancer.

Daniel J. Park, J. Benítez, G. Giles, 2012, American journal of human genetics.

Methylation of the BRCA1 promoter is associated with decreased BRCA1 mRNA levels in clinical breast cancer specimens.

I. Andrulis, H. Ozçelik, J. Rice, 2000, Carcinogenesis.

Mutation in the coding region of the BRCA1 gene leads to aberrant splicing of the transcript

H. Ozçelik, J. Murphy, B. Rosen, 1999, Human mutation.

Germline mutations in CDH1 are infrequent in women with early-onset or familial lobular breast cancers

O. Olopade, M. Southey, P. Miron, 2010, Journal of Medical Genetics.

JMEDGENET79814 1..5

O. Olopade, M. Southey, P. Miron, 2022 .

p53 mutations in mammary ductal carcinoma in situ but not in epithelial hyperplasias.

I. Andrulis, M. Redston, H. Ozçelik, 1998, Cancer research.

Low levels of expression of an inhibitor of cyclin-dependent kinases (CIP1/WAF1) in primary breast carcinomas with p53 mutations.

S. Mousses, I. Andrulis, H. Ozçelik, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Amplification of the gene for histidyl-tRNA synthetase in histidinol-resistant Chinese hamster ovary cells

L. Siminovitch, H. Murialdo, I. Andrulis, 1985 .

Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations.

I. Andrulis, J. Knight, P. Goodwin, 1999, Journal of the National Cancer Institute.

Rare Mutations in XRCC 2 Increase the Risk of Breast Cancer

J. Benítez, G. Giles, S. Buys, 2022 .

Heteroduplex and protein truncation analysis of the BRCA1 185delAG mutation

I. Andrulis, H. Ozçelik, D. Cole, 1996, Human Genetics.

Validation study of the lambda model for predicting the BRCA1 or BRCA2 mutation carrier status of North American Ashkenazi Jewish women

G. Glendon, C. Apicella, H. Ozçelik, 2007, Clinical genetics.

p53 missense mutations in microdissected high-grade ductal carcinoma in situ of the breast.

M. Redston, S. Bull, S. Done, 2001, Journal of the National Cancer Institute.

Multiplex PCR-SSCP for simultaneous screening for mutations in several exons of p53.

H. Ozçelik, I. Andrulis, 1995, BioTechniques.